Table 1. Characteristics of the 59 children at baseline, at time of first neuro-imaging.
| Characteristics | |
| Sex, N (%) | |
| Male | 28 (47) |
| Female | 31 (53) |
| Ethnicity, N (%) | |
| Black | 40 (68) |
| Caucasian | 6 (10) |
| Black/caucasian | 7 (12) |
| Other1 | 6 (10) |
| Date of birth, N (%) | |
| Before 1996 | 19 (32) |
| Between 1996–2003 | 34 (58) |
| After 2003 | 6 (10) |
| CDC-classification, N (%) | |
| N | 5 (9) |
| A | 13 (22) |
| B | 15 (25) |
| C | 25 (42) |
| Unknown | 1 (2) |
| CD4+ T cell % nadir | 20 |
| Median (IQR) | (9–34) |
| CD4+ T cell % at baseline | 29 |
| Median (IQR) | (19–36) |
| Lost to follow-up, N (%) | 2 (3) |
| ART experience, N (%) | |
| No therapy | 5 (8) |
| Mono or dual therapy | 2 (3) |
| PI-based cART | 12 (20) |
| NNRTI-based cART | 9 (15) |
| Both PI- and NNRTI-based cART | 10 (17) |
| Duration of ART experience | 1.6 |
| Median years (IQR) | (0.3–5.8) |
| Age at start ART | 2.6 |
| Median years (IQR) | (0.8–5.9) |
| HIV VL <400 copies/ml, N (%) | 14 (24) |
| HIV VL at start ART | 5.3 |
| Median log copies/ml (IQR) | (4.4–6.0) |
ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; VL, viral load;
1
Other included Asian ethnicity or unknown.